Using an antibody specific for dually phosphorylated extracellular-regulate
d kinases 1 and 2, we have examined 82 primary and metastatic prostate tumo
r specimens for the presence of activated mitogen-activated protein (MAP) k
inase, Nonneoplastic prostate tissue showed little or no staining with acti
vated MAP kinase antiserum. In prostate tumors, the level of activated MAP
kinase increased with increasing Gleason score and tumor stage. In a separa
te analysis, tumor samples from two patients showed no activation of MAP ki
nase before androgen ablation therapy; however, following androgen ablation
treatment, high levels of activated MAP kinase were detected in the recurr
ent tumors. Collectively, these data suggest an increase in the activation
of the MAP kinase signal transduction pathway as prostate cancer progresses
to a more advanced and androgen-independent disease.